Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
04:15pm, Tuesday, 21'st Apr 2026
DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U
Rapid oral presentation of PD-L1 subgroup data from HERIZON-GEA-01 evaluating zanidatamab combinations, and additional analyses of tolerability, biomarker response and real-world treatment patterns in
Assetmark Inc. Buys 5,499 Shares of Jazz Pharmaceuticals PLC $JAZZ
03:24am, Tuesday, 21'st Apr 2026
Assetmark Inc. grew its position in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 102.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor own
Choreo LLC Acquires Shares of 2,883 Jazz Pharmaceuticals PLC $JAZZ
04:36am, Sunday, 19'th Apr 2026
Choreo LLC bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) during the undefined quarter, according to its most recent 13F filing with the SEC. The fund bought 2,883 shares o
KBC Group NV Boosts Position in Jazz Pharmaceuticals PLC $JAZZ
04:13am, Saturday, 18'th Apr 2026
KBC Group NV boosted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 7.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. T
Jazz Pharmaceuticals Touts Record $4.3B 2025 Revenue, Reaffirms 2026 Outlook at Conference
01:05am, Saturday, 18'th Apr 2026
Jazz Pharmaceuticals (NASDAQ: JAZZ) executives highlighted record 2025 revenue, a growing pipeline anchored by oncology programs, and a refined strategy emphasizing rare diseases during a conference s
Jazz Pharmaceuticals plc (JAZZ) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
04:11pm, Wednesday, 15'th Apr 2026
Jazz Pharmaceuticals plc (JAZZ) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
2,979 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Aaron Wealth Advisors LLC
03:09am, Friday, 10'th Apr 2026
Aaron Wealth Advisors LLC bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The
Six abstracts, including one oral presentation, underscore Jazz's ongoing commitment to generating real-world evidence addressing rare neurological disorders, including rare and severe forms of epilep
Capricorn Fund Managers Ltd Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ
04:44am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fi
Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock
04:50am, Sunday, 05'th Apr 2026
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ - Get Free Report) Director Bruce Cozadd sold 6,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an averag
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
04:15pm, Wednesday, 01'st Apr 2026
DUBLIN, April 1, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 25th Annual Needham Healthcare Conference. Company management wi
Why Is Jazz (JAZZ) Down 3.9% Since Last Earnings Report?
12:32pm, Thursday, 26'th Mar 2026
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Joint initiative aims to provide scientific validation for patient empowerment, clinician education on lower sodium intake and cardiovascular comorbidity awareness CHICAGO, March 24, 2026 /PRNewswire/
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
07:44am, Wednesday, 18'th Mar 2026
Seven presentations deliver new insights into zanidatamab's differentiated HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones, and advancing research on JZP898, a conditi
